Samuel Fisch has served as the Executive Director, Investor Relations & Corporate Communications since April 2019. He is responsible for strengthening and expanding our investor base globally and acts as a primary point of contact for our investor community.
Samuel brings a strong background of experience in investor relations and capital markets. Prior to joining Veru, Samuel worked at Solebury Trout. During his time there, he worked with both private and public healthcare companies on investor relations, corporate strategy, and equity capital market advisory throughout all stages of development.
Samuel holds a BBA from Elon University.
Org chart
Teams
This person is not in any teams
Offices
Veru
Veru is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancers.
